Top

Breast Cancer Research and Treatment

Published in:

01-10-2010 | Letter to the Editor

The role of RACK1 as an independent prognostic indicator in human breast cancer

Authors: Sara Al-Reefy, Kefah Mokbel

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Excerpt

To the Editor, …

Cao XX, Xu JD, Liu XL, Xu JW, Wang WJ, Li QQ, Chen Q, Xu ZD, Liu XP (2010) RACK1: promotes breast carcinoma proliferation, invasion and metastasis in vitro and in vivo. Breast Cancer Res Treat

Kissil JL, Deiss LP, Bayewitch M, Raveh T, Khaspekov G, Kimchi A (1995) Isolation of DAP3, a novel mediator of interferon-gamma-induced cell death. J Biol Chem 270:27932–27936CrossRefPubMed

Mamidipudi V, Cartwright CA (2009) A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways. Oncogene 28(50):4421–4433 [Epub 2009 Sep 21]

Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, Li QQ, Xu ZD, Liu XP (2010) RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat [Epub ahead of print]. doi:10.1007/s10549-010-0955-3

Cao XX, Xu JD, Liu XL, Xu JW, Cheng YY, Wang WJ, Li QQ, Chen Q, Xu ZD, Liu XP (2009) RACK1: a superior independent predictor for poor clinical outcome in breast cancer. Int J Cancer [Epub ahead of print]. doi:10.1002/ijc.25120

Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, Wang WJ, Li QQ, Chen Q, Xu ZD, Liu XP (2009) RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat [Epub ahead of print]. doi:10.1007/s10549-009-0657-x

Wang Z, Jiang L, Huang C, Li Z, Chen L, Gou L, Chen P, Tong A, Tang M, Gao F, Shen J, Zhang Y, Bai J, Zhou M, Miao D, Chen Q (2008) Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics 7:1639–1650CrossRefPubMed

Wang Z, Zhang B, Jiang L, Zeng X, Chen Y, Feng X, Guo Y, Chen Q (2009) RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. Eur J Cancer 45:490–496CrossRefPubMed

Title: The role of RACK1 as an independent prognostic indicator in human breast cancer
Authors: Sara Al-Reefy
Kefah Mokbel
Publication date: 01-10-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1020-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2010

Subtypes of familial breast tumours revealed by expression and copy number profiling

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer

NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis

Estrogen deficiency and bone loss in women with breast cancer

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer